Valuation: Mymetics Corp

Market Cap 439K 380K 353K 325K 615K 41.85M 623K 4.17M 1.63M 20.83M 1.65M 1.61M 68.89M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.43M 58.11M 53.43M 101M 6.88B 102M 686M 269M 3.42B 271M 265M 11.32B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 58 2012-11-18
Change 5-day change 1-year change 3-year change Capi.($)
-11.43%+44.21% - - 45
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average -1.26%-3.79%+35.87%+154.81% 25.98B
Weighted average by Cap. +0.23%-2.96%+30.79%+116.84%

Financials

2021 2022
Net sales 430K 372K 346K 319K 602K 41.02M 610K 4.09M 1.6M 20.42M 1.61M 1.58M 67.51M 1.03M 890K 828K 762K 1.44M 98.06M 1.46M 9.78M 3.83M 48.81M 3.86M 3.78M 161M
Net income -4.73M -4.09M -3.81M -3.5M -6.63M -451M -6.71M -44.98M -17.62M -225M -17.76M -17.37M -743M -4.8M -4.16M -3.87M -3.56M -6.73M -458M -6.82M -45.69M -17.9M -228M -18.04M -17.65M -754M
Net Debt 67.1M 58.08M 54.06M 49.71M 94.01M 6.4B 95.25M 638M 250M 3.19B 252M 246M 10.54B 71.68M 62.05M 57.75M 53.1M 100M 6.84B 102M 682M 267M 3.4B 269M 263M 11.26B
Logo Mymetics Corp
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-